Editas Medicine Business Summary

Editas Medicine, Inc. (EDIT) is a clinical-stage biotechnology company that generates revenue through strategic collaboration agreements, milestone payments, and the licensing of its foundational CRISPR/Cas9 and CRISPR/Cas12a intellectual property. The company’s primary business segments are centered on the development of transformative genomic medicines, with a recent strategic pivot to a "fully in vivo" focus following the discontinuation of its ex vivo reni-cel program in late 2024. Its lead development candidate, EDIT-401, is an in vivo gene-editing therapy targeting hyperlipidemia by reducing LDL cholesterol. Editas operates in a highly competitive landscape alongside direct rivals such as CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Beam Therapeutics (BEAM), and Caribou Biosciences (CRBU). While its peers have achieved earlier regulatory milestones in ex vivo applications, Editas distinguishes itself by leveraging its proprietary Cas12a system and focusing on differentiated in vivo delivery to address large-market cardiovascular and rare genetic indications. The company was founded in 2013 by a preeminent team of CRISPR pioneers, including George M. Church, Feng Zhang, Jennifer Doudna, J. Keith Joung, and David Liu. The current leadership team is led by President and CEO Gilmore O’Neill, M.B., M.M.Sc., who joined in 2022 after serving as Chief Medical Officer at Sarepta Therapeutics and holding senior roles at Biogen. Key executives include Chief Financial Officer Amy Parison, who succeeded Erick Lucera in March 2025, and Chief Scientific Officer Linda C. Burkly, Ph.D., a veteran of Biogen with over 35 years of translational research experience. Bruce E. Eaton serves as Executive Vice President, Chief Technology Officer, and Chief Business Officer. The company is overseen by an independent Board of Directors chaired by Jessica Hopfield, Ph.D., who was appointed Chair in December 2024. Notable institutional backing includes Flagship Pioneering, Polaris Partners, Third Rock Ventures, Casdin Capital, and Google Ventures (GV).